RESUMEN

Quinolin-2-ones bearing a heteroaryl-piperazine linked by a two carbon chain at the 3- or 4-position were synthesised and evaluated as mixed 5-HT(1B)/5-HT(2A) receptor antagonists. Potent mixed antagonists were obtained with thieno[3,2-c]pyridine derivatives. In this series, compound 2.1 (SL 65.0472) proved to be functional antagonist at both the 5-HT(2A) receptor (rat in vivo 5-HT-induced hypertension model) and the 5-HT(1B) receptor (dog in vitro saphenous vein assay).

Asunto(s)

Piperazinas/síntesis química , Quinolinas/síntesis química , Receptores de Serotonina/metabolismo , Antagonistas de la Serotonina/síntesis química , Animales , Perros , Piperazinas/química , Piperazinas/farmacología , Quinolinas/química , Quinolinas/farmacología , Ratas , Receptor de Serotonina 5-HT1B , Receptor de Serotonina 5-HT2A , Receptores de Serotonina/efectos de los fármacos , Antagonistas de la Serotonina/química , Antagonistas de la Serotonina/farmacología

RESUMEN

5-hydroxytryptamine (5-HT) contracts vascular smooth muscle and pharmacological and molecular biological data suggest that these effects are mediated primarily by stimulation of 5-HT(1B) and 5-HT(2A) receptor subtypes. We have studied the properties of 7-fluoro-2-oxo-4-[2-[4-(thieno[3,2-c] pyridin-4-yl) piperazin-1-yl] ethyl]-1,2-dihydroquinoline-1-acetamide (SL 65.0472 ), a novel 5-HT receptor antagonist, in isolated vascular preparations contracted by 5-HT or sumatriptan. In canine isolated saphenous vein strips (putatively 5-HT(1B)-mediated contraction), SL 65.0472 antagonised sumatriptan-induced contractions in a competitive manner (pA(2) 8. 17+/-0.36). 5-HT contracts rabbit aorta by stimulation of 5-HT(2A) receptors. SL 65.0472 displaced the 5-HT concentration response curve in rabbit aorta rightwards with a significant reduction in maximum. The apparent pK(B) value was 8.58+/-0.18. 5-HT-induced contractions of human coronary arteries are mediated by a mixed population of 5-HT(1B) and 5-HT(2A) receptors. SL 65.0472 produced rightward parallel shifts of the 5-HT concentration response curves in all tissues studied (pA(2) 8.8+/-0.14, n=7). In conclusion, SL 65. 0472 is a potent antagonist of vascular smooth muscle contraction in vitro mediated by 5-HT receptor stimulation.

Asunto(s)

Aorta/efectos de los fármacos , Vasos Coronarios/efectos de los fármacos , Piperazinas/farmacología , Quinolinas/farmacología , Vena Safena/efectos de los fármacos , Antagonistas de la Serotonina/farmacología , Vasoconstricción/efectos de los fármacos , Animales , Aorta/fisiología , Vasos Coronarios/fisiología , Perros , Femenino , Depuradores de Radicales Libres/farmacología , Humanos , Masculino , Piperazinas/química , Quinolinas/química , Conejos , Receptor de Serotonina 5-HT1B , Receptor de Serotonina 5-HT2A , Receptores de Serotonina/efectos de los fármacos , Receptores de Serotonina/fisiología , Vena Safena/fisiología , Serotonina/farmacología , Antagonistas de la Serotonina/química , Sumatriptán/farmacología , Vasoconstricción/fisiología , Vasoconstrictores/farmacología

RESUMEN

The effects of alpha-1-adrenoceptor antagonists on the concentration-response curves (CRC) to phenylephrine and oxymetazoline have been studied in prostatic urethra and trigone of male adult rabbits (28 wk old). WB4101 and phentolamine, at low concentrations which should preferentially antagonize the alpha-1A-adrenoceptor subtype, did not modify the oxymetazoline-induced contraction of both prostatic urethra and trigone, suggesting that alpha-1A-adrenoceptors are not activated under these conditions. In urethra, pretreatment with 50 microM chloroethylclonidine (CEC), significantly reduced the maximal contraction to both agonists to 60 and 70% of control, respectively. In trigone, CEC decreased the maximum contraction to phenylephrine, but not to oxymetazoline, by 50%. In addition, CEC shifted to the right the CRC to both agonists. These results suggest the presence of an alpha-1B-adrenoceptor in both rabbit urethra and trigone. Exposure to prazosin (0.01-1 microM) significantly shifted to the right the CRC to phenylephrine (pA2 or affinity values without CEC treatment: 7.77 and 7.96 in urethra and trigone respectively; with CEC pretreatment: 7.49 and 7.42, respectively). When oxymetazoline was used as an agonist and in the presence of CEC, prazosin was unexpectedly weak in urethra with an affinity value of 6.70, although the antagonist potency was not modified in trigone (affinity 7.38). These values suggest that alpha-1-adrenoceptor agonists contract rabbit urethra and trigone through activation of alpha-1-adrenoceptors displaying low affinity for prazosin. Whether this receptor coincides with the alpha-1L- or alpha-1N-subtype remains to be clarified.

Asunto(s)

Agonistas Adrenérgicos/farmacología , Contracción Muscular/efectos de los fármacos , Próstata/efectos de los fármacos , Receptores Adrenérgicos alfa 1/efectos de los fármacos , Uretra/efectos de los fármacos , Animales , Relación Dosis-Respuesta a Droga , Masculino , Norepinefrina/farmacología , Oximetazolina/farmacología , Fenilefrina/farmacología , Conejos

RESUMEN

This study demonstrated the existence of a specific binding site for angiotensin IV in porcine aortic endothelial cells. Non-equilibrium kinetic analyses at 37 degrees C allowed the calculation of a kinetic Kd of 0.44 nM. Pseudo-equilibrium saturation binding studies at 37 degrees C for 90 min indicated the presence of a single high-affinity site (Kd = 3.87 +/- 0.60 nM), saturable and abundant (Bmax = 9.64 +/- 1.44 pmol/mg protein). Competitive binding studies demonstrated the following rank order of effectiveness: angiotensin IV > angiotensin III > angiotensin II > angiotensin I > angiotensin II-(1-7), while 2-n-butyl-4-chloro-5-hydroxymethyl-1 [(2'-(1H-tetrazol-5-yl) biphenyl-4-yl) methyl] imidazol (DuP 753: losartan), 1-(4-amino-3-methyl-phenyl) methyl-5-diphenylisoethyl-4,5,6,7-tetrahydro-1H-imidazo [4,5-C] pyridine-6-carboxylic acid (PD 123177) or nicotinic acid-Tyr-(N alpha -benzyl-oxycarbonyl-Arg) Lys-His-Pro-Ile-OH (CGP 42112A) were inactive at the concentration of 100 microM. This binding site is, therefore, distinct from angiotensin II receptors, AT1 and AT2. Addition of the divalent cations Mg2+, Mn2+ or Ca2+ to the incubation buffer resulted in 90-95% inhibition of the [125I]angiotensin IV-specific binding to porcine aortic endothelial cells. Furthermore, the chelator, EGTA, at 5 mM increased the number of binding sites (Bmax = 17.8 +/- 2.5 pmol/mg protein), with no change in affinity (Kd = 5.7 +/- 1.3 nM). Exposure of porcine aortic endothelial cell membranes to the non-hydrolyzable GTP analog, GTP gamma S, had no effect on [125I]angiotensin IV binding. The presence of a high concentration of binding sites for angiotensin IV in porcine aortic endothelial cells suggests that this peptide may play an important role in the modulation of the cardiovascular system.

Asunto(s)

Angiotensina II/análogos & derivados , Endotelio Vascular/metabolismo , Angiotensina II/metabolismo , Animales , Aorta , Sitios de Unión/efectos de los fármacos , Unión Competitiva , Cationes Bivalentes/farmacología , Células Cultivadas , Ácido Egtácico/farmacología , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/ultraestructura , Cinética , Unión Proteica/efectos de los fármacos , Porcinos

RESUMEN

1. This study was undertaken in cultured vascular smooth muscle cells to characterize the angiotensin II (AII) AT1 receptor subtype involved in DNA synthesis because (i) the AII receptor involved in vascular proliferation has previously been characterized in vitro in rat aortic cells and identified as an AT1 subtype and (ii) molecular cloning and biochemical studies have provided evidence for the existence of different AT1 receptor subtypes. 2. In cultured rat aortic vascular smooth muscle (VSMC), exposure to AII (0.1 to 100 nM) resulted in a concentration-dependent increase in [3H]-thymidine incorporation with an EC50 of 1.41 +/- 0.51 nM. Maximal stimulation was observed in the presence of 100 nM AII and corresponded to 271 +/- 40% of basal [3H]-thymidine incorporation. 3. To characterize the AII AT1 receptor subtype involved in this effect, cells were exposed to AII (3 nM) in the absence or presence of increasing concentrations of various AII receptor antagonists. The stimulatory effect of AII (3 nM) on [3H]-thymidine incorporation in VSMC was antagonized by the non-selective AT1/AT2 receptor antagonist, [Sar1, Ile8]-AII (IC50 = 5.6 nM), by the AT1A/AT1B receptor antagonist, losartan (IC50 = 10.5 nM) and the AT1 receptor antagonist, L-158809 (IC50 = 0.20 nM). The selective AT2 receptor ligand, CGP 42112A, antagonized AII-induced [3H]-thymidine incorporation with an IC50 of 6.3 +/- 1.3 microM while the AT2/AT1B receptor antagonist, PD 123319, was found to be almost inactive (IC50 > 10 microM). 4. Under the same experimental conditions, angiotensin III (AIII) was found to be at least 50 times less potent than All with an apparent EC50 of 81.6 +/- 7.7 nM. At the highest concentration tested (10 microM),the effect of AIII corresponded to 327 +/- 61% of basal [3H]-thymidine incorporation.5. These results confirm that All can stimulate DNA synthesis in VSMC through an AT, receptor.Furthermore, the pharmacological characterization of this AT1 receptor is compatible with the ATlA receptor subtype recently described on cultured mesangial cells since (i) the ATIA/ATIB receptor antagonist losartan is active at nanomolar concentrations, (ii) micromolar concentrations of the AT2/AT1B receptor antagonist PD 123319 are ineffective at antagonizing the AII-induced [3H]-thymidine incorporation and (iii) All is at least 50 times more potent than AIII in stimulating DNA synthesis.

Asunto(s)

Angiotensina II/farmacología , ADN/biosíntesis , Músculo Liso Vascular/metabolismo , Receptores de Angiotensina/fisiología , 1-Sarcosina-8-Isoleucina Angiotensina II/farmacología , Animales , Células Cultivadas , Masculino , Músculo Liso Vascular/citología , Factor de Crecimiento Derivado de Plaquetas/farmacología , Ratas , Ratas Endogámicas WKY , Receptores de Angiotensina/clasificación , Timidina/metabolismo

RESUMEN

One novel, potent and selective alpha-2 adrenoceptor antagonist is 2-(4,5-dihydro-1H-imidazol-2-yl)-1,2,4,5-tetrahydro-2- propylpyrrolo[3,2,1-hi]-indole hydrochloride (SL 84.0418). It inhibits with high affinity the radioligand binding to rat cortical alpha-2 adrenoceptors, as well as to human platelet alpha-2 adrenoceptors labeled with [3H]idazoxan (Ki = 7 nM). SL 84.0418 has low affinity for alpha-1 adrenoceptors labeled with [3H]prazosin (Ki = 3.3 microM). In vitro, SL 84.0418 has no alpha agonist properties, whereas it is a potent alpha-2 adrenoceptor antagonist at both pre- and postsynaptic alpha-2 adrenoceptors. In contrast, it possesses low potency as an antagonist at postsynaptic alpha-1 adrenoceptors demonstrating a more than 1000-fold selectivity toward alpha-2 compared with alpha-1 adrenoceptors. In the same tests, the alpha-2 adrenoceptor antagonist idazoxan had a selectivity ratio of 200. SL 84.0418 is the racemic mixture of two enantiomers, SL 86.0715 [(+) enantiomer] and SL 86.0714 [(-) enantiomer]. The alpha-2 adrenoceptor blocking activities reside with SL 86.0715. Similar to idazoxan, SL 84.0418 increases in a concentration-dependent manner the electrically evoked release of [3H]norepinephrine from rat hypothalamic slices through the blockade of the presynaptic inhibitory alpha-2 adrenoceptors. In isolated hamster adipocytes, SL 84.0418 potently antagonizes the inhibition of lipolysis induced by UK 14,304. In addition, SL 84.0418 inhibits epinephrine-induced aggregation of rabbit platelets, effects mediated by postsynaptic alpha-2 adrenoceptors. SL 84.0418 does not inhibit (IC50 > 1,000 nM) radioligand binding to other receptors or recognition sites, nor does it inhibit calcium, sodium or potassium channels.(ABSTRACT TRUNCATED AT 250 WORDS)

Asunto(s)

Antagonistas Adrenérgicos alfa/farmacología , Indoles/farmacología , Pirroles/farmacología , Animales , Sitios de Unión , Cricetinae , Perros , Técnicas In Vitro , Indoles/metabolismo , Canales Iónicos/efectos de los fármacos , Lipólisis/efectos de los fármacos , Masculino , Mesocricetus , Norepinefrina/metabolismo , Agregación Plaquetaria/efectos de los fármacos , Inhibidores de Agregación Plaquetaria/farmacología , Pirroles/metabolismo , Conejos , Ratas , Ratas Sprague-Dawley , Receptores Adrenérgicos alfa/metabolismo

RESUMEN

In the rat brain, the presynaptic 5-hydroxytryptamine (5-HT) autoreceptors located on 5-HT terminals correspond to the 5-HT1B subtype. The presence of a 5-HT receptor probably located on 5-HT nerve endings and modulating transmitter release in the human neocortex has been reported, but its detailed pharmacological characterization is not yet available. On the other hand, receptor binding and autoradiographic results indicate that the 5-HT1B receptor subtype is not present in the human brain. We, therefore, studied the modulation of the electrically evoked release of [3H]5-HT by various 5-HT receptor agonists and antagonists in preloaded slices of human neocortex obtained from 18 patients undergoing neurosurgery. The nonselective 5-HT1A/1B/1D receptor agonist 5-carboxamidotryptamine produced a potent inhibition (70% at 0.03 microM) of the electrically evoked release of [3H]5-HT which was blocked by 5-HT receptor antagonists with the following relative order of potency: methiothepin greater than metergoline = methysergide greater than propranolol. The selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin at 0.1 microM did not modify the electrically evoked release of [3H]5-HT. The 5-HT1A/1B receptor agonist RU 24969 was 10 times more potent at inhibiting [3H]5-HT overflow in the rat frontal cortex than in the human neocortex. The potent 5-HT1B receptor antagonist cyanopinodolol did not modify the 5-carboxamidotryptamine-induced inhibition of the electrically evoked release of [3H]5-HT in slices of the human neocortex, but produced by itself a small inhibition of [3H]5-HT overflow.(ABSTRACT TRUNCATED AT 250 WORDS)

Asunto(s)

Corteza Cerebral/metabolismo , Receptores de Serotonina/metabolismo , Serotonina/metabolismo , Adolescente , Antagonistas Adrenérgicos alfa/farmacología , Adulto , Anciano , Animales , Niño , Dioxanos/farmacología , Estimulación Eléctrica , Femenino , Humanos , Idazoxan , Técnicas In Vitro , Indoles/farmacología , Masculino , Persona de Mediana Edad , Ratas , Ratas Sprague-Dawley , Serotonina/análogos & derivados , Serotonina/farmacología , Antagonistas de la Serotonina , Tritio , Yohimbina/farmacología

RESUMEN

The effectiveness of presynaptic receptor agonists to inhibit the electrically evoked release of [3H]monoamines from brain slices is attenuated in the presence of blockade of neuronal uptake for the serotonin (5-HT) and the norepinephrine (NE) systems. There is controversy, however, as to the existence of a functional link between the presynaptic receptors and the neuronal uptake carriers. An alternative hypothesis involves competition for the presynaptic receptor sites between the exogenous agonist and the released neurotransmitter. In order to examine the proposed functional interaction, we studied the alpha-2 adrenoceptor-mediated inhibition of the electrically evoked release of [3H]-5-HT from slices of the rat hypothalamus, a model in which endogenous NE does not activate the alpha-2 heteroreceptors located on 5-HT terminals. The inhibitors of 5-HT uptake, citalopram (0.01-1 microM) and paroxetine (1 microM), which by themselves did not modify [3H]-5-HT release, antagonized the inhibition of [3H]-5-HT overflow produced by UK 14.304, an alpha-2 adrenoceptor agonist. The inhibition of the electrically evoked release of [3H]-5-HT by exogenous NE (0.1-1 microM) was also attenuated in the presence of citalopram. In contrast, citalopram did not modify the electrically evoked release of [3H]-NE or the inhibition of [3H]-NE release mediated by UK 14.304. When the 5-HT autoreceptor was blocked by cyanopindolol, the inhibitory effect of UK 14.304 on [3H]-5-HT release was unaltered in the presence of citalopram.(ABSTRACT TRUNCATED AT 250 WORDS)

Asunto(s)

Citalopram/farmacología , Hipotálamo/efectos de los fármacos , Piperidinas/farmacología , Receptores Adrenérgicos alfa/efectos de los fármacos , Antagonistas de la Serotonina/farmacología , Serotonina/metabolismo , Animales , Tartrato de Brimonidina , Fenclonina/farmacología , Técnicas In Vitro , Masculino , Norepinefrina/farmacología , Paroxetina , Quinoxalinas/farmacología , Ratas , Ratas Endogámicas , Receptores de Serotonina/efectos de los fármacos

RESUMEN

In superfused rat hypothalamic slices prelabelled with [3H]-noradrenaline, the alpha 2-adrenoceptor agonist UK 14304 inhibited in a concentration-dependent manner the electrically-evoked release of tritium. This inhibition was antagonized by the alpha 2-adrenoceptor blocking agent idazoxan, which by itself increased the electrically-evoked tritium overflow. Exposure to forskolin, an adenylate cyclase activator, increased the electrically-evoked release of [3H]-noradrenaline. In the presence of forskolin (1 mumol/l), both the inhibitory effect of UK 14304 and the increasing effect of idazoxan on the electrically-evoked release of [3H]-noradrenaline were less pronounced than in the absence of the adenylate cyclase activator. Exposure to forskolin and to the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine shifted to the right the concentration-effect curve for UK 14304 in a similar manner as that observed in the presence of forskolin alone. Exposure to phorbol-12,13-dibutyrate (0.01-10 mumol/l), a drug which activates protein kinase C, increased the electrically-evoked release of [3H]-noradrenaline. In the presence of phorbol-12,13-dibutyrate (0.1 and 1 mumol/l), the concentration effect curve for UK 14304 on tritium overflow was significantly shifted to the right. The increasing effect of idazoxan on tritium overflow was significantly less pronounced in the presence of 1 mumol/l phorbol-12,13-dibutyrate. In superfused rat hypothalamic slices prelabelled with [3H]-5-hydroxytryptamine, the alpha 2-adrenoceptor agonist UK 14304 significantly inhibited the electrically-evoked release of tritium. Exposure to forskolin increased in a concentration-dependent manner [3H]-5-hydroxytryptamine overflow, but did not modify the UK 14304-mediated inhibition. Exposure to 3-isobutyl-1-methylxanthine enhanced the electrically-evoked release of [3H]-5-hydroxytryptamine. In the presence of both forskolin (1 mumol/l) and 3-isobutyl-1-methylxanthine (1 mmol/l), the concentration-response curve for UK 14304 was significantly shifted to the right. Exposure to phorbol-12,13-dibutyrate (0.01-10 mumol/l) enhanced in a concentration-dependent manner the electrically-evoked overflow of [3H]-5-hydroxytryptamine. In the presence of phorbol-12,13-dibutyrate (0.1 and 1 mumol/l), UK 14304 was significantly less potent to inhibit tritium release than in the absence of the protein kinase C activator. It is concluded that both cyclic AMP and phosphoinositide turnover are involved in the modulation of noradrenaline and 5-hydroxytryptamine release by presynaptic alpha 2-adrenoceptors in rat hypothalamic slices. However, these interactions do not represent definitive proof for a cause-effect relationship for the second messengers mediating the alpha 2-adrenoceptor induced inhibition of transmitter release either as autoreceptor or as heteroreceptor.

Asunto(s)

Adenilil Ciclasas/metabolismo , Hipotálamo/metabolismo , Norepinefrina/metabolismo , Proteína Quinasa C/metabolismo , Receptores Adrenérgicos alfa/fisiología , Serotonina/metabolismo , 1-Metil-3-Isobutilxantina/farmacología , Animales , Antihipertensivos/farmacología , Tartrato de Brimonidina , Colforsina/farmacología , Dioxanos/farmacología , Estimulación Eléctrica , Hipotálamo/enzimología , Idazoxan , Técnicas In Vitro , Masculino , Forbol 12,13-Dibutirato/farmacología , Quinoxalinas/farmacología , Ratas , Ratas Endogámicas

RESUMEN

[3H]-Paroxetine binding to rabbit blood platelet membranes from samples obtained under light and dark conditions was examined. Animals were kept on a 14 h light (L) - 10 h dark (D) schedule and blood samples were collected at L + 7 and D + 5 h. Significant differences were found for Bmax values of [3H]-paroxetine binding, with low Bmax values during the light period and high Bmax values during the dark period. The Kd values were not significantly different. These results confirm previous observations on light-dark differences of [3H]-imipramine binding in rabbit blood platelets suggesting the existence of a circadian rhythm for the 5-HT transporter complex.

Asunto(s)

Plaquetas/metabolismo , Piperidinas/metabolismo , Antagonistas de la Serotonina/metabolismo , Animales , Membrana Celular/metabolismo , Ritmo Circadiano , Oscuridad , Imipramina/metabolismo , Técnicas In Vitro , Luz , Masculino , Paroxetina , Conejos

RESUMEN

Platelet [3H]-imipramine binding was studied in patients with Alzheimer's disease and control subjects matched to the patients for age and sex. There were no differences in the binding parameters of [3H]-imipramine on platelet membranes from patients with Alzheimer's disease, when compared with the control group. These results suggest that [3H]-imipramine binding could be a useful tool to discriminate between demented and depressive patients in elderly populations.

Asunto(s)

Enfermedad de Alzheimer/sangre , Plaquetas/metabolismo , Proteínas Portadoras , Imipramina/farmacocinética , Receptores de Droga , Receptores de Neurotransmisores/metabolismo , Anciano , Anciano de 80 o más Años , Trastorno Depresivo/sangre , Femenino , Humanos , Masculino

RESUMEN

The high-affinity binding of [3H]imipramine is associated with the serotonin (5-hydroxytryptamine; 5-HT) transporter in the brain and in platelets. In the rat hypothalamus it has been reported that the density of these sites is increased in the dark period of the day, and this could result in an alteration in the release of 5-HT. The electrically evoked release of [3H]5-HT was thus studied in preloaded hypothalamic slices prepared from rats kept under 12:12 h light/dark or dark/light schedules. The fractional release of [3H]5-HT evoked by electrical stimulation, but not by the 5-HT releasing agent fenfluramine, was significantly decreased during the dark period when compared with the light period. The effects of the 5-HT reuptake blocker citalopram, of the two 5-HT autoreceptor agonists 5-methoxytryptamine and RU 24969, and of the 5-HT autoreceptor antagonist methiothepin on the release of [3H]5-HT were the same in both groups of rats. In conclusion, the release of [3H]5-HT from prelabelled rat hypothalamic slices is decreased during the dark period of the day. This modification is not reflected by changes in the effects of citalopram, an inhibitor of 5-HT reuptake, to modify the overflow of [3H]5-HT. The sensitivity and efficacy of agonists of the 5-HT autoreceptor are the same during the light and dark periods of the day.

Asunto(s)

Ritmo Circadiano , Hipotálamo/metabolismo , Serotonina/metabolismo , 5-Metoxitriptamina/farmacología , Animales , Proteínas Portadoras/metabolismo , Citalopram/farmacología , Estimulación Eléctrica , Fenfluramina/farmacología , Hipotálamo/efectos de los fármacos , Indoles/farmacología , Masculino , Metiotepina/farmacología , Ratas , Ratas Endogámicas , Receptores de Serotonina/efectos de los fármacos , Receptores de Serotonina/metabolismo

RESUMEN

In superfused rat hypothalamic slices prelabeled with [3H]-5-hydroxytryptamine [( 3H]-5-HT), the 5-HT autoreceptor agonists 5-methoxytryptamine and RU 24969 inhibited in a concentration-dependent manner the electrically evoked release of [3H]-5-HT. Exposure to phorbol-12,13-dibutyrate increased in a concentration-dependent manner the stimulation-evoked overflow of [3H]-5-HT and shifted to the right the 5-methoxytryptamine inhibition curve. Exposure to forskolin, a potent activator of adenylate cyclase, increased the stimulation-evoked [3H]-5-HT overflow and shifted to the left the 5-methoxytryptamine or RU 24969 inhibitory curves on transmitter release. A similar interaction was observed in the presence of 1-isobutyl,3-methylxanthine (IBMX), a phosphodiesterase inhibitor, or 8-bromo-cyclic AMP and the serotonin autoreceptor agonist 5-methoxytryptamine. In the presence of phorbol-12,13-dibutyrate or forskolin, the enhancing effect of the 5-HT autoreceptor antagonist methiothepin on the stimulation-evoked [3H]-5-HT overflow was significantly less pronounced than in the absence of these compounds. These results indicate that the presynaptic 5-HT autoreceptors that modulate the release of [3H]-5-HT in rat hypothalamic slices may be coupled to the phosphoinositide cycle and protein kinase C-dependent mechanisms. In addition, the increase in intracellular level of cyclic AMP by forskolin, IBMX, and 8-bromo-cyclic AMP potentiates the inhibitory effects of the autoreceptor agonist 5-methoxytryptamine on [3H]-5-HT release, although the mechanism of the interaction remains to be elucidated.

Asunto(s)

Colforsina/farmacología , Hipotálamo/efectos de los fármacos , Forbol 12,13-Dibutirato/farmacología , Serotonina/metabolismo , 1-Metil-3-Isobutilxantina/farmacología , 5-Metoxitriptamina/farmacología , 8-Bromo Monofosfato de Adenosina Cíclica/farmacología , Animales , Interacciones Farmacológicas , Sinergismo Farmacológico , Estimulación Eléctrica , Potenciales Evocados/efectos de los fármacos , Hipotálamo/metabolismo , Indoles/farmacología , Masculino , Metiotepina/farmacología , Ésteres del Forbol/farmacología , Polimixina B/farmacología , Ratas , Ratas Endogámicas

RESUMEN

The overflow of tritium from stimulated rat hypothalamic slices preincubated with [3H]-serotonin (5-HT) was significantly enhanced by reducing the frequency of stimulation from 3 Hz to 1 Hz while keeping the number of impulses constant. The 5-HT receptor agonist 5-methoxytryptamine inhibited in a concentration-dependent manner the electrically-evoked release of [3H]-5-HT with IC50 values of 560 nmol/l and of 34 nmol/l when the stimulations were delivered at 3 Hz and 1 Hz, respectively. The terminal 5-HT autoreceptor antagonist methiothepin enhanced in a concentration-dependent manner the electrically-evoked release of [3H]-5-HT and this effect was greater at a frequency of stimulation of 3 Hz than at 1 Hz. In the same paradigm, the 5-HT reuptake inhibitors citalopram and paroxetine did not alter the overflow of radioactivity elicited by stimulation at 3 Hz but significantly decreased it at 1 Hz. In the presence of 5-HT autoreceptor blockade achieved with methiothepin, citalopram increased the overflow of [3H]-5-HT to the same extent at 1 Hz and at 3 Hz. The IC50 values for inhibition of [3H]-5-HT release by the selective alpha 2-adrenoceptor agonist UK 14.304 were 35 nmol/l at 3 Hz and 30 nmol/l at 1 Hz. It is concluded that modulation of 5-HT release by 5-HT autoreceptors, but not by alpha 2-adrenoceptors is dependent on the synaptic concentration of 5-HT as a function of the frequency of depolarization.

Asunto(s)

Antagonistas Adrenérgicos alfa/farmacología , Hipotálamo/metabolismo , Receptores de Serotonina/metabolismo , Serotonina/metabolismo , 5-Metoxitriptamina/farmacología , Animales , Antihipertensivos/farmacología , Tartrato de Brimonidina , Citalopram/farmacología , Estimulación Eléctrica , Hipotálamo/efectos de los fármacos , Hipotálamo/fisiología , Técnicas In Vitro , Masculino , Paroxetina , Piperidinas/farmacología , Quinoxalinas/farmacología , Ratas , Ratas Endogámicas , Receptores de Serotonina/efectos de los fármacos

RESUMEN

5-Methoxytryptamine is a potent agonist of presynaptic 5-hydroxytryptamine autoreceptors modulating serotonin release in the central nervous system. This methoxyindole can be synthesized in the pineal gland, but its presence in vivo is still controversial, probably because of rapid catabolism by monoamine oxidase. An improved high-pressure liquid chromatography method, with coulometric detection, has been developed for the simultaneous measurement of melatonin, 5-methoxytryptamine, 5-methoxytryptophol and 5-methoxyindolacetic acid. We have demonstrated a day-night rhythmicity in the amount of 5-methoxytryptamine in the pineal gland of golden hamsters (Mesocricetus auratus) maintained under a long photoperiod (14 h light: 10 h darkness) and pretreated with the monoamine oxidase inhibitor pargyline. Levels of 5-methoxytryptamine were highest at 16.30 h and lowest at 00.30 h. The rhythm for 5-methoxytryptamine appears to be the same as for serotonin (opposite in phase to that of melatonin). The identification of 5-methoxytryptamine has been confirmed by analysis with gas chromatography-mass spectrometry.

Asunto(s)

5-Metoxitriptamina/biosíntesis , Ritmo Circadiano , Glándula Pineal/metabolismo , Serotonina/biosíntesis , Animales , Cromatografía Líquida de Alta Presión , Cricetinae , Cromatografía de Gases y Espectrometría de Masas , Ácido Hidroxiindolacético/análogos & derivados , Ácido Hidroxiindolacético/análisis , Indoles/análisis , Masculino , Melatonina/análisis , Mesocricetus

RESUMEN

[3H]-Imipramine and [3H]-paroxetine label with high affinity a recognition site which is associated with the serotonergic transporter in blood platelets. The pharmacological profile of [3H]-imipramine and [3H]-paroxetine binding is highly correlated with the potency of drugs to inhibit the uptake of serotonin. Dissociation kinetic experiments suggest that the substrate recognition site for serotonin may be different from the modulatory site which is labeled with [3H]-imipramine or [3H]-paroxetine. The existence of an endocoid acting on the imipramine receptor to modulate the serotonin transporter has been proposed by several laboratories. In clinical studies most laboratories have reported a decrease in Bmax of [3H]-imipramine binding in platelets from depressed untreated patients when compared with matched healthy volunteers. The Bmax of [3H]-imipramine binding in platelets appears to be a state-dependent biological marker in depression.

Asunto(s)

Plaquetas/metabolismo , Proteínas Portadoras/sangre , Animales , Antidepresivos Tricíclicos/farmacología , Sitios de Unión , Humanos , Imipramina/antagonistas & inhibidores , Imipramina/metabolismo , Paroxetina , Piperidinas/metabolismo , Antagonistas de la Serotonina/farmacología

RESUMEN

Platelet [3H]-5HT uptake, [3H]-imipramine binding and endogenous 5HT levels were measured in healthy volunteers during short-term (20 days) administration of lithium, and following its withdrawal. The Vmax of [3H]-5HT uptake was significantly decreased during lithium treatment. Following lithium withdrawal, platelet [3H]-5HT uptake (Vmax) remained decreased and was followed by a pronounced rebound effect in some of the subjects for up to 3 months. The affinity constant (Km) of [3H]-5HT uptake was not modified. Binding of tritiated imipramine during the same period and platelet 5HT levels measured till 14 days after withdrawal was not affected by lithium treatment. As lithium is devoid of in vitro effects on both 5HT uptake and imipramine binding, it is concluded that the effects of lithium on the 5HT transporter do not reflect a direct effect on the transporter complex. Our results indicate that lithium-induced changes at the level of 5HT uptake in platelets are not correlated with concomitant variations in platelet 5HT content and can be dissociated from modifications at the level of imipramine binding sites within the macromolecular complex of the 5HT transporter. Moreover, platelet 5HT uptake is apparently modulated by lithium, with a similar pattern in healthy volunteers and in manic-depressive patients.

Asunto(s)

Plaquetas/metabolismo , Imipramina/metabolismo , Litio/farmacología , Serotonina/metabolismo , Adulto , Plaquetas/efectos de los fármacos , Femenino , Humanos , Imipramina/sangre , Litio/administración & dosificación , Masculino , Serotonina/sangre , Factores de Tiempo

RESUMEN

[3H]-imipramine binding was measured in rabbit blood platelet membranes on a 24 h cycle. Animals were kept on a 14 h light (L) 10 h dark (D) schedule, and blood samples were collected at L + 2, L + 8, D + 2, D + 8 and L + 2 h on a following cycle. Significant differences were found for Bmax values of [3H]-imipramine binding, with highest values during the dark phase and lowest during the light phase. No significant differences were found in Kd values. These results suggest the existence of a circadian rhythm for the Bmax of [3H]-imipramine binding in blood platelets.

Asunto(s)

Plaquetas/metabolismo , Ritmo Circadiano , Imipramina/metabolismo , Animales , Imipramina/sangre , Técnicas In Vitro , Masculino , Conejos

RESUMEN

The 5-hydroxytryptamine (5-HT) autoreceptor antagonist methiothepin increased in a concentration-dependent manner the K+-evoked release of [3H]-noradrenaline in pineal glands from normal and parachlorophenylalanine (PCPA)-treated rats. However, 5-HT and the 5-HT receptor agonists, LSD and 5-methoxytryptamine, were inactive at modulating the K+-evoked release of [3H]-noradrenaline in pineal glands from normal and PCPA-treated rats. When tested on the uptake of [3H]-noradrenaline in the pineal gland, methiothepin was found to be a potent inhibitor (IC50 = 10.6 nmol/l). Exposure to methiothepin failed to increase the K+-evoked release of [3H]-noradrenaline when tested in the presence of cocaine. While the K+-evoked release of [3H]-noradrenaline was shown to be modulated through inhibitory presynaptic alpha 2-adrenoceptors in pineal glands from normal and PCPA-treated rats, no evidence was obtained for a presynaptic modulation through 5-HT receptors of [3H]-noradrenaline release. The facilitation by methiothepin of the K+-evoked release of [3H]-noradrenaline in rat pineal gland appears to be due to the inhibition of noradrenaline uptake by this compound.

Asunto(s)

Dibenzotiepinas/farmacología , Metiotepina/farmacología , Norepinefrina/metabolismo , Glándula Pineal/metabolismo , Potasio/farmacología , Animales , Cromatografía Líquida de Alta Presión , Dioxanos/farmacología , Fenclonina/farmacología , Idazoxan , Técnicas In Vitro , Masculino , Glándula Pineal/efectos de los fármacos , Ratas , Ratas Endogámicas , Antagonistas de la Serotonina/farmacología , Yohimbina/farmacología

RESUMEN

In rat hypothalamic slices prelabeled with [3H]-5-hydroxytryptamine ([3H]-5-HT), exposure to the 5-HT receptor agonist lysergic acid diethylamide (0.1-1 microM) or 5-methoxytryptamine (0.1-10 microM) decreased in a concentration-dependent manner the release of 3H-transmitter elicited by high K+ or electrical stimulation. Exposure to the 5-HT autoreceptor antagonist methiothepin (0.1-1 microM) increased in a concentration-dependent manner the K+ stimulation-evoked overflow of [3H]-5-HT and a similar increase was observed under conditions of electrical stimulation. In contrast, exposure to the nontricyclic 5-HT uptake inhibitor citalopram (0.1-1 microM) did not modify by itself the electrically evoked overflow of [3H]-5-HT, but increased in a concentration-dependent manner the release of 3H-transmitter elicited by K+ stimulation. This effect of citalopram on transmitter release was potentiated when the endogenous stores of 5-HT were depleted by pretreatment with para-chlorophenylalanine methyl ester (300 mg/kg i.p.). Citalopram was shown previously to antagonize the inhibition by lysergic acid diethylamide of the electrically evoked release of [3H]-5-HT in rat hypothalamic slices. Yet, this inhibitor of neuronal uptake of 5-HT did not antagonize the effects of lysergic acid diethylamide when the release of [3H]-5-HT was evoked by K+ depolarization. Electrical stimulation represents a more physiological experimental model for transmitter release than exposure to high K+, and therefore the interaction between 5-HT uptake blockade and presynaptic inhibitory 5-HT autoreceptors, observed in the hypothalamus with electrical stimulation but not with K+ depolarization, remains of biological relevance.

Asunto(s)

Hipotálamo/metabolismo , Inhibidores de la Captación de Neurotransmisores/farmacología , Potasio/farmacología , Receptores de Serotonina/efectos de los fármacos , Serotonina/metabolismo , 5-Metoxitriptamina/farmacología , Animales , Citalopram , Estimulación Eléctrica , Fenclonina/farmacología , Hipotálamo/efectos de los fármacos , Técnicas In Vitro , Dietilamida del Ácido Lisérgico/farmacología , Masculino , Metiotepina/farmacología , Propilaminas/farmacología , Ratas , Ratas Endogámicas , Sodio/metabolismo